Search results for "drug toxicity"

showing 7 items of 7 documents

Sustained low-efficiency dialysis (SLED) for acute lithium intoxication

2008

Acute lithium intoxication may cause serious neurologic and cardiac manifestations, up to the patient's death. Owing to its low molecular weight, relatively small volume of distribution close to that of total body water, and its negligible protein binding, lithium can be efficiently removed by any extracorporeal modality of renal replacement therapy (RRT). However, the shift from the intracellular to the extracellular compartment, with the inherent rebound phenomenon after the end of RRT, might limit the efficacy of the conventional, short-lasting haemodialysis. There have been no published studies up to now concerning the use of sustained low-efficiency dialysis (SLED) in lithium intoxicat…

Bradycardiamedicine.medical_specialtyLithium (medication)medicine.medical_treatmentCase Reportchemistry.chemical_compoundOliguriamedicineRenal replacement therapyDialysisbipolar disorderTransplantationbusiness.industryLithium carbonateGastric lavagedrug toxicitypsychotropic drugsSurgerychemistrylithiumNephrologyAnesthesiadialysisHemodialysismedicine.symptombusinessmedicine.drugClinical Kidney Journal
researchProduct

Cardiovascular effect of dental anesthesia with articaine (40 mg with epinefrine 0,5 mg % and 40 mg with epinefrine 1 mg%) versus mepivacaine (30 mg …

2011

Objectives: The aim of the present study is to compare cardiovascular safety profiles of two dental anesthetics: articaine versus two standard mepivacaine solutions used during etiological periodontal treatment in cardiovascular patients. Study Design: Using a cross-over study design, ten cardiovascular patients were randomly assigned to dental treatment with 1.8mL of a local anesthetic injected on each quadrant of the mouth: Articaine (40mg with Epinephrine 0.5mg % and 40mg with Epinephrine 1mg %) or Mepivacaine (30mg and 20mg with Epinephrine 1mg %). A computer programme enabled continuous longitudinal data collection: O2 saturation, blood pressure (BP) and heart rate (HR). Results: No se…

Epinephrinemedicine.drug_classAnesthesia DentalMepivacaineBlood PressureCarticaineArticaineDrug toxicityCarticaineDental anesthesiaHeart RatemedicineHumansVasoconstrictor AgentsSingle-Blind MethodProspective StudiesAnesthetics LocalGeneral DentistryCross-Over StudiesLocal anestheticbusiness.industryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Crossover studyAnesthetics CombinedDental anesthesiaCardiovascular diseasesEpinephrineBlood pressureOtorhinolaryngologyCardiovascular DiseasesAnesthesiaUNESCO::CIENCIAS MÉDICASMepivacaineChronic periodontitisResearch-ArticleSurgerybusinessPtes Especiales and Bioengineering in Dentistrymedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.

1980

Summary— Forty-two patients with previously untreated T3/4 N1-4 MO/1 prostatic adenocarcinoma were treated with either cyproterone acetate (n=21; 300 mg intramuscularly per week) or oestradiol undecylate (n=21; 100 mg intramuscularly per month) after extensive staging which included open skeletal biopsy and pelvic lymphadenectomy in some cases. Subjective and objective parameters as well as signs of drug toxicity were recorded regularly. Evaluation after 6 months showed cyproterone acetate to be more effective in the following respects: (1) the significantly different castration effect as judged by plasma testosterone, (2) the objective voiding pattern and tumour response, with regression o…

Malemedicine.medical_specialtyTime FactorsUrologyUrologyAdenocarcinomachemistry.chemical_compoundRandom AllocationBiopsymedicineHumansCyproteronePelvic lymphadenectomyDrug toxicityTestosteroneAgedClinical Trials as Topicmedicine.diagnostic_testEstradiolProstatic adenocarcinomabusiness.industryCyproterone acetateCancerProstatic NeoplasmsMiddle Agedmedicine.diseaseSurgeryCastrationchemistrybusinessBritish journal of urology
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy

2011

A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…

SorafenibNiacinamideMalemedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsPyridinesAntineoplastic AgentsEPATOCARCINOMAlaw.inventionRandomized controlled triallawDrug ToxicityInternal medicinemedicineHumansProspective StudiesHCCProspective cohort studySurvival analysisAgedHCC; sorafenibHepatologybusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularSorafenibMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryHepatocellular carcinoma sorafenibRegimenTUMORI DEL FEGATOTolerabilityItalyHepatocellular carcinomaDisease ProgressionsorafenibFemaleLiver cancerbusinessmedicine.drug
researchProduct

Effect of intravitreal injection of Indocyanine Green, Triamcinolone Acetonide and Trypan Blue on the electroretinographic response of rats

2007

International audience; Purpose:: Indocyanine Green (ICG) and Tripan Blue (TB) are commonly used in macular surgery by making easier the internal limiting membrane (ILM) removing. However, the innocuousness of these dyes is not actually established notably for ICG. Then, several authors proposed the use of triamcinolone acetonide (TA) as an alternative to the use of intraoperative dyes for visualizing the ILM. The purpose of this study was to evaluate the effects of intravitreal injection of ICG, TB and TA on the rat electroretinogram (ERG). Methods:: Three groups of 12-week-old Sprague Dawley rats (n=6) received intravitreal injection in one eye of 0.1mL of either ICG 0.5mg/mL, TB 3mg/mL o…

[SDV] Life Sciences [q-bio]retinagenetic structures[SPI.GPROC] Engineering Sciences [physics]/Chemical and Process Engineeringdrug effects[SDV]Life Sciences [q-bio][SDV.IDA]Life Sciences [q-bio]/Food engineering[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineeringsense organs[SDV.IDA] Life Sciences [q-bio]/Food engineeringelectroretinography: non-clinicaleye diseasesdrug toxicity
researchProduct

Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome

2019

What is known and objective Mebendazole (MBZ) is a broad-spectrum antihelminthic agent of the benzimidazole type. Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare. We report a case of severe hepatitis after administration of MBZ in a patient with Gilbert's syndrome affected by pinworms infestation. Case summary Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time. After 18 days from the start of therapy, he developed hepatomegaly, and increases in hepatic enzymes and bilirubin. Hepatic enzymes returned to normal over the foll…

medicine.medical_specialtyGlucuronosyltransferaseSettore MED/17 - Malattie InfettiveBilirubinMebendazoleGlucuronidation030226 pharmacology & pharmacyGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicinePharmacology (medical)030212 general & internal medicinePharmacologyHepatitisLiver injurybiologybusiness.industrydrug toxicity Gilbert's syndrome hepatitis mebendazolemedicine.diseaseAntihelminthic AgentGilbert's syndromechemistrySettore BIO/14 - Farmacologiabiology.proteinbusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct